BIXT (Bioxytran) Risk Assessment

View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Bioxytran is: No Data: Cannot be evaluated.

Competitive Comparison of Bioxytran's Risk Assessment

For the Biotechnology subindustry, Bioxytran's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioxytran's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Bioxytran's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Bioxytran (OTCPK:BIXT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Bioxytran Risk Assessment Related Terms

Thank you for viewing the detailed overview of Bioxytran's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioxytran Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 2nd Avenue, Suite 605, Needham, MA, USA, 02494

Website

https://www.bioxytraninc.com

Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.

Executives

David Platt	director, 10 percent owner, officer: CEO	12 APPLETON CIRCLE, NEWTON MA 02459
Dale H Conaway	director	189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter	director	BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
Hana Chen-walden	director	7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh	officer: Chief Communication Officer	1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer	other: No longer 10% owner	PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist	10 percent owner, officer: CFO	47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber	director, officer: President	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig	director, officer: Secretary/Treasurer	78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc	10 percent owner	1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai	10 percent owner	20443 TIMBERLINE, BEND OR 97701